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**Value of the data**--This work provides a deeper understanding of the prevalence, etiologies and prognosis of heart failure in SSA.--The data allow examination of the different medications used for the treatment of heart failure and therefore could help in changing practices for an optimal management of this pathology.--The data could be used as a baseline for comparison in future studies.

1. Data {#s0005}
=======

In SSA, heart failure is a major public health problem, associated with high morbidity and mortality. Due to the shortage of data to distinctly understand the epidemiology of this pathology in this part of the world, we present here a summary of available data on the prevalence, aetiology, treatment, and prognosis of heart failure in SSA.

2. Experimental design, materials, and methods {#s0010}
==============================================

Through a systematic literature search in MEDLINE and EMBASE (search strategies are presented in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}), we included all published studies from January 1, 1996 to June 23, 2017 with available data on the prevalence, incidence, aetiologies, diagnosis, treatment and outcomes of heart failure in patients aged 12 years and older, living in SSA. We excluded studies conducted exclusively on African populations living outside Africa, commentaries, editorials, letters to the editor, case reports and case-series of less than 30 participants, studies lacking relevant data to compute the prevalence of the different heart failure aetiologies or treatment, and for duplicate studies, the most comprehensive and/or recent study with the largest sample size was considered, studies with inaccessible full-text, even after request from the corresponding author.Table 1Main search strategy for PubMed.Table 1SearchSearch termHits1Heart failure \[tiab\] OR cardiac failure \[tiab\] OR cardiac insufficiency \[tiab\] OR heart disease \[tiab\]276, 0882(((Africa\* \[tiab\] OR Benin \[tiab\] OR Botswana \[tiab\] OR \"Burkina Faso\" \[tiab\] OR Burundi \[tiab\] OR Cameroon \[tiab\] OR \"Canary Islands\" \[tiab\] OR \"Cape Verde\" \[tiab\] OR \"Central African Republic\" \[tiab\] OR Chad \[tiab\] OR Comoros \[tiab\] OR Congo \[tiab\] OR \"Democratic Republic of Congo\" \[tiab\] OR Djibouti \[tiab\] OR \"Equatorial Guinea\" \[tiab\] OR Eritrea \[tiab\] OR Ethiopia \[tiab\] OR Gabon \[tiab\] OR Gambia \[tiab\] OR Ghana \[tiab\] OR Guinea \[tiab\] OR \"Guinea Bissau\" \[tiab\] OR \"Ivory Coast\" \[tiab\] OR \"Cote d\'Ivoire\" \[tiab\] OR Jamahiriya \[tiab\] OR Kenya \[tiab\] OR Lesotho \[tiab\] OR Liberia \[tiab\] OR Madagascar \[tiab\] OR Malawi \[tiab\] OR Mali \[tiab\] OR Mauritania \[tiab\] OR Mauritius \[tiab\] OR Mayotte \[tiab\] OR Mozambique \[tiab\] OR Namibia \[tiab\] OR Niger \[tiab\] OR Nigeria \[tiab\] OR Principe \[tiab\] OR Reunion \[tiab\] OR Rwanda \[tiab\] OR \"Sao Tome\" \[tiab\] OR Senegal \[tiab\] OR Seychelles \[tiab\] OR \"Sierra Leone\" \[tiab\] OR Somalia \[tiab\] OR \"South Africa\" \[tiab OR \"St Helena\" \[tiab\] OR Swaziland \[tiab\] OR Tanzania \[tiab\] OR Togo \[tiab\] OR Uganda \[tiab\] OR Zaire \[tiab\] OR Zambia \[tiab\] OR Zimbabwe \[tiab\] OR \"Central Africa\" \[tiab\] OR \"Central African\" \[tiab\] OR \"West Africa\" \[tiab\] OR \"West African\" \[tiab\] OR \"Western Africa\" \[tiab\] OR \"Western African\" \[tiab\] OR \"East Africa\" \[tiab\] OR \"East African\" \[tiab\] OR \"Eastern Africa\" \[tiab\] OR \"Eastern African\" \[tiab\] OR \"South African\" \[tiab\] OR \"Southern Africa\" \[tiab\] OR \"Southern African\" \[tiab\] OR \"sub Saharan Africa\" \[tiab\] OR \"sub Saharan African\" \[tiab\] OR \"subSaharan Africa\" \[tiab\] OR \"subSaharan African\" \[tiab\]) NOT (\"guinea pig\" \[tiab\] OR \"guinea pigs\" \[tiab\] OR \"aspergillus niger \[tiab\]\"))) AND (Heart failure \[tiab\] OR cardiac failure \[tiab\] OR cardiac insufficiency \[tiab\] OR heart disease \[tiab\])3\#1 AND \#250124\#3 AND **Search limits**: From 1 January 1996 to 10 Oct 20172125Table 2Main search strategy for EMBASE.Table 2\#1'Heart failure' OR 'cardiac failure' OR 'cardiac insufficiency' OR 'heart disease'658,990\#2\'africa\':ab,ti OR \'algeria\':ab,ti OR \'angola\':ab,ti OR \'benin\':ab,ti OR \'botswana\':ab,ti OR \'burkina faso\':ab,ti OR \'burundi\':ab,ti OR \'cameroon\':ab,ti OR \'canary islands\':ab,ti OR \'cape verde\':ab,ti OR \'central african republic\':ab,ti OR \'chad\':ab,ti OR \'comoros\':ab,ti OR \'congo\':ab,ti OR \'democratic republic of congo\':ab,ti OR \'djibouti\':ab,ti OR \'egypt\':ab,ti OR \'equatorial guinea\':ab,ti OR \'eritrea\':ab,ti OR \'ethiopia\':ab,ti OR \'gabon\':ab,ti OR \'gambia\':ab,ti OR \'ghana\':ab,ti OR \'guinea\':ab,ti OR \'guinea bissau\':ab,ti OR \'ivory coast\':ab,ti OR \'cote d ivoire\':ab,ti OR \'jamahiriya\':ab,ti OR \'kenya\':ab,ti OR \'lesotho\':ab,ti OR \'liberia\':ab,ti OR \'libya\':ab,ti OR \'madagascar\':ab,ti OR \'malawi\':ab,ti OR \'mali\':ab,ti OR \'mauritania\':ab,ti OR \'mauritius\':ab,ti OR \'mayotte\':ab,ti OR \'morocco\':ab,ti OR \'mozambique\':ab,ti OR \'namibia\':ab,ti OR \'niger\':ab,ti OR \'nigeria\':ab,ti OR \'principe\':ab,ti OR \'reunion\':ab,ti OR \'rwanda\':ab,ti OR \'sao tome\':ab,ti OR \'senegal\':ab,ti OR \'seychelles\':ab,ti OR \'sierra leone\':ab,ti OR \'somalia\':ab,ti OR \'south africa\':ab,ti OR \'st helena\':ab,ti OR \'sudan\':ab,ti OR \'swaziland\':ab,ti OR \'tanzania\':ab,ti OR \'togo\':ab,ti OR \'tunisia\':ab,ti OR \'uganda\':ab,ti OR \'western sahara\':ab,ti OR \'zaire\':ab,ti OR \'zambia\':ab,ti OR \'zimbabwe\':ab,ti OR \'central africa\':ab,ti OR \'central african\':ab,ti OR \'west africa\':ab,ti OR \'west african\':ab,ti OR \'western africa\':ab,ti OR \'western african\':ab,ti OR \'east africa\':ab,ti OR \'east african\':ab,ti OR \'eastern africa\':ab,ti OR \'eastern african\':ab,ti OR \'north africa\':ab,ti OR \'north african\':ab,ti OR \'northern africa\':ab,ti OR \'northern african\':ab,ti OR \'south african\':ab,ti OR \'southern africa\':ab,ti OR \'southern african\':ab,ti OR \'sub saharan africa\':ab,ti OR \'sub saharan african\':ab,ti OR \'subsaharan africa\':ab,ti OR \'subsaharan african\':ab,ti408,647\#3\#1 AND \#24165\#4\#3 AND **Search limits**: From 1 January 1996 to 10 Oct 20171660

The titles and abstracts of articles retrieved from the bibliographic searches were independently screened by two investigators and full-texts of potentially eligible studies were retrieved and assessed for final inclusion. All discrepancies the selection of studies were resolved through discussion or with the arbitrage of a third investigator. A total of 35 studies were included in this review [@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35]. A summary of the selection process is presented in the [Fig. 1](#f0005){ref-type="fig"}.Fig. 1PRISMA flow chart of study selection.Fig. 1

Data were then extracted using a predesigned data extraction form. The extracted data include: the last name of first author and the year of study publication, the country in which the study was conducted, Region (Western, Southern, Central, Eastern), area (urban, semi-urban or rural), study design (cross-sectional, cohort, case control), data collection (prospective versus retrospective), random sampling (yes versus no), study population, male proportion, mean or median age (in years), age range (in years), sample size, criteria used for the diagnosis of heart failure, number of cases of the different aetiologies of heart failure and number of cases of the different medications used for the treatment of heart failure.

The quality and risk of bias of all included studies are presented in [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}. It was assessed using the risk of bias assessment tool for developed by Hoy et al. [@bib36]. This tool was adapted for the different topics on heart failure covered in this review (prevalence, aetiology, treatment and prognosis of heart failure).Table 3Summary table of included studies reporting on heart failure in sub-Saharan Africa (1996--2017).Table 3First name of author, publication yearCountryRegionAreaStudy designStudy settingData collectionStudy populationRandom samplingMale (%)Mean age (in years)Age range (in years)Sample sizeCriteria for diagnosis of HFOyoo, 1999 [@bib1]KenyaEasternUrbanCross-sectionalHospital-basedProspectivePatients ≥13 years admitted for congestive heart failureNo48.4NR≥1391NRThiam, 2003 [@bib2]SenegalWesternUrbanCross-sectionalHospital- basedProspectivePatients suffering from heart failureNoNR50.012--91170NRKingue, 2005 [@bib3]CameroonCentralUrbanCross-sectionalHospital-basedRetrospective and prospectivePatients presenting with clinical and echocardiographic signs of heart failureNo59.357.3≥16167NRFamiloni, 2007 [@bib4]NigeriaWesternSemi-urbanCross-sectionalHospital-basedProspectivePatients presenting with acute heart failureNo61.757.6NR82NROwusu, 2007 [@bib5]GhanaWesternUrbanCross-sectionalHospital-basedProspectivePatients above 12 years admitted with diagnosis of heart failureNo51.551.113--90167Framingham\'s criteriaStewart, 2008 [@bib6]South AfricaSouthernUrbanCross-sectionalHospital-basedProspectiveNovo presentations in patients with heart failure and related cardiomyopathiesNo4355.0NR884European Society of Cardiology (ESC) guidelines on HFOgah, 2008 [@bib7]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveAll cases of echocardiography done in the department of medicine between September 2005 and February 2007No51.654.015--901441NROnwuchekwa, 2009 [@bib8]NigeriaWesternNRCross-sectionalHospital-basedRetrospectiveCongestive cardiac failure cases admitted and/or discharged from the medical wardsNo57.254.418--100423Framingham\'s criteriaMaro, 2009 [@bib9]TanzaniaEasternUrbanCohortHospital-basedProspectivePatients admitted for congestive heart failureNo55.0NRNR390Framingham\'s criteriaDamasceno, 2012 [@bib10]The THESUS-HF registrySSA--CohortHospital-basedProspectivePatients admitted with acute heart failureNo49.252.3˃121006European Society of Cardiology (ESC) guidelines on HFChansa, 2012 [@bib11]ZambiaSouthernUrbanCohortHospital-basedProspectiveAdult patients ([\>]{.ul}18 years) admitted for acute heart failureNo4150[\>]{.ul}18390European Society of Cardiology guidelines on HFKwan, 2013 [@bib12]RwandaEasternRuralCross-sectionalHospital-basedRetrospectiveHeart failure patients treated between November 2006 and march 2011No30.0NRNR138NRMassouré, 2013 [@bib13]DjiboutiEasternNRCohortHospital-basedProspectiveDjiboutian adults hospitalized for heart failureNo84.055.827--7545Framingham\'s criteriaOjji, 2013 [@bib14]NigeriaWesternUrbanCross-sectionalHospital-basedProspectiveSubjects of African descent with novo presentations of heart diseaseNo49.349.0NR1515European Society of Cardiology guidelines on HFSliwa, 2013 [@bib15]The THESUS-HF registrySSA--CohortHospital-basedProspectivePatients presenting with acute heart failureNo49.152.3[\>]{.ul}121006European Society of Cardiology guidelines on HFMakubi, 2014 [@bib16]TanzaniaEasternUrbanCohortHospital-basedProspectivePatients ≥ 18 years of age with heart failure defined by the Framingham criteriaNo49.055.0≥18427Framingham\'s criteriaOgah, 2014 [@bib17]NigeriaWesternUrbanCross-sectionalHospital-basedProspectivePatients presenting with acute heart failureNo54.956.4NR452Framingham\'s criteria and ESCPio, 2014 [@bib18]TogoWesternUrbanCross-sectionalHospital-basedProspectiveHospitalized patients with heart failureNo48.252.218--106297European Society of Cardiology guidelines on HFPio, 2014 [@bib19]TogoWesternUrbanCross-sectionalHospital-basedRetrospectiveFiles of patients hospitalized with heart failureNoNR36.518--45376NROsuji, 2014 [@bib20]NigeriaWesternNRCross-sectionalHospital-basedRetrospectiveAll medical admissionNo50.560.718--110537NROkello, 2014 [@bib21]UgandaEasternNRCohortHospital-basedRetrospectivePatients admitted for acute heart failureNo30.352NR274NRDokainish, 2015 [@bib22]The INTER-CHF registrySSA--CohortHospital-basedProspective, international, multicenterAmbulatory and hospitalized adult patients with heart failureYes51.853.4≥181294Boston criteria of HFAdeoti, 2015 [@bib23]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveAll medical admissionsNo55.050.916--1023750NRAnsa, 2016 [@bib24]NigeriaWesternNRCross-sectionalHospital-basedRetrospective medical record reviewAll cardiovascular admissions to the medical wardsNoNRNR≥18144NRAbebe 2016 [@bib25]EthiopiaEasternUrbanChart reviewHospital-basedRetrospectiveMedical records of patients admitted for heart failureNR30.253.6NR311NRAli, 2016 [@bib26]EthiopiaEasternUrbanCohortHospital-basedProspectiveAdult patients ([\>]{.ul}18 years) admitted for heart failureNo50.750.9NR152Framingham\'s criteriaKingery, 2017 [@bib27]TanzaniaEasternUrbanCohortHospital-basedProspectiveMedical inpatients admitted for heart failureNo44.152.0≥18145Framingham\'s criteriaBoombhi, 2017 [@bib28]CameroonCentralUrbanCross-sectionalHospital-basedRetrospectivePatients hospitalized for acute heart failure, diagnosed on clinical and/or ultrasound evidenceNo42.761,516--95148NRTraore, 2017 [@bib29]Ivory CoastWesternUrbanCross-sectionalHospital-basedRetrospectivePatients hospitalized for heart failureNo51.0NRNR257NRBonsu, 2017 [@bib30]GhanaWesternUrbanCohortHospital-basedRetrospectiveIndividuals aged ≥ 18 years discharged from first heart failure admissionNo45.660.3≥181488Framingham\'s criteriaMwita, 2017 [@bib31]BotswanaSouthernUrbanCohortHospital-basedProspectivePatients admitted with acute heart failureNo53.954.220--89193NRPallangyo 2017 [@bib32]TanzaniaEasternUrbanCohortHospital-basedProspectiveAdult patients ([\>]{.ul}18 years) admitted for heart failureNo43.546.4[\>]{.ul}18463Framingham\'s criteriaSani, 2017 [@bib33]The THESUS-HF registrySSA--CohortHospital-basedProspectivePatients presenting with acute heart failureNo49.252.3[\>]{.ul}12954European Society of Cardiology guidelines on HFOgah, 2014 [@bib34]NigeriaWesternUrbanCohortHospital-basedProspectivePatients followed up for heart failureNo53.158.0NR239NRCarlson, 2017 [@bib35]Kenya; UgandaEasternNRCross sectionalHospital-basedProspectiveHealth facilities with available diagnostic technologies for HF diagnosisNoNANANA340 health facilities (197 in Uganda and 143 in Kenya)NA[^1]Table 4Summary tables for studies reporting on the prevalence of heart failure sub-Saharan Africa.Table 4First name of author, publication yearCountryRegionAreaStudy designStudy settingData collectionRandom samplingPopulationMale (%)Mean ageAge range (in years)Sample sizeHF diagnostic toolPrevalence of HF (%)Study qualityOsuji, 2014 [@bib20]NigeriaWesternNRCross-sectionalHospital-basedRetrospectiveNoPatients admitted to the medical ward50.560.718--110537NR30.9ModerateKingue, 2005 [@bib3]CameroonCentralUrbanChart reviewHospital-basedRetrospectiveNoPatient [\>]{.ul}16 years admitted for cardiac pathologies59.357.3NR144Echocardiography30ModerateAnsa, 2016 [@bib24]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveNoAll cases of medical admissions38.95547--65339NR42.5LowPio, 2014 [@bib18]TogoWesternUrbanCross-sectionalHospital-basedRetrospectiveNoPatients admitted to the cardiology unitNR52.218--106297Echocardiagraphy25.6HighPio, 2014 [@bib19]TogoWesternUrbanCross-sectionalHospital-basedRetrospectiveNoPatients admitted to the cardiology unitNR36.518--45376Echocardiagraphy28.6LowOgah, 2014 [@bib17]NigeriaWesternUrbanCohortHospital-basedProspectiveNoAll medical admission54.956.4NR452Echocardiagraphy9.4HighAdeoti, 2015 [@bib23]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveNoAll medical admissions55.050.916--1023750NR11.0Moderate[^2]Table 5Aetiologies of heart failure across sub-Saharan Africa (1996--2017).Table 5First name of author, publication yearCountryRegionAreaStudy designStudy settingData collectionStudy populationRandom samplingMale (%)Mean age (in years)Age range (in years)Sample sizeCriteria for diagnosis of HFAetiology of heart failureDiagnostic criteria of IHDStudy qualityOyoo, 1999 [@bib1]KenyaEasternUrbanCross-sectionalHospital-basedProspectivePatients ≥13 years admitted for congestive heart failureNo48.4NR≥1391NRRheumatic heart disease (32%); Cardiomyopathy (25.2%); Hypertensive heart disease (17.6%), pericardial disease (13.2%); Cor pulmonale (7.7%); Ischaemic heart disease (2.2%); Congenital heart disease (2.2%).ECG and 2D Doppler EchocardiographyModerateThiam, 2003 [@bib2]SenegalWesternUrbanCross-sectionalHospital- basedProspectivePatients suffering from heart failureNoNR50.012--91170NRHypertension heart disease (34%); Valvular heart diseases (45%); Chronic renal failure (14.5%); Ischaemic heart disease (18.9%); Pulmonary embolism with Right heart failure (3.5%) and aetiology unspecified (6%)Clinical presentation ECG and EchocardiographyHighKingue, 2005 [@bib3]CameroonCentralUrbanCross-sectionalHospital-basedRetrospective and prospectivePatients presenting with clinical and echocardiographic signs of heart failureNo59.357.3≥16167NRHypertensive heart disease (54.5%); Cardiomyopathies (26.3%); Rheumatic heart disease (24.6%), Valvular heart diseases (24.6%), Ischaemic heart disease (2.4%).12-lead ECG and EchocardiographyModerateFamiloni, 2007 [@bib4]NigeriaWesternSemi-urbanCross-sectionalHospital-basedProspectivePatients presenting with acute heart failureNo61.757.6NR82NRHypertensive heart disease (43.4%); Dilated cardiomyopathy (28%); Rheumatic heart disease (9.8%), Endomyocardial fibrosis (2.2%); Cor pulmonale (3.7%); Ischaemic heart disease (8.5%); others (3.5%)NRModerateOwusu, 2007 [@bib5]GhanaWesternUrbanCross-sectionalHospital-basedProspectivePatients above 12 years admitted with diagnosis of heart failureNo51.551.113--90167Framingham criteriaHypertensive heart disease (42.5%); Rheumatic heart disease (21.6%); Dilated cardiomyopathy (17.4%); pericardial disease (4.2%); Ischaemic heart disease (3.6%); Cor pulmonale (2.4%) and Congenital heart disease (2.4%)12-lead ECG and EchocardiographyHighStewart, 2008 [@bib6]South AfricaSouthernUrbanCross-sectionalHospital-basedProspectiveNovo presentations in patients with heart failure and related cardiomyopathiesNo4355.0NR884ESCDilated cardiomyopathy (35%); Hypertensive heart disease (33%); Right heart failure (27%); Ischaemic heart disease (9%) and Valvular heart disease (8%)12-lead ECG; echocardiography; stress test; cardiac nuclear imaging and cardiac catheterizationHighOgah, 2008 [@bib7]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveAll cases of echocardiography done in the department of medicine between September 2005 and February 2007No51.654.015--901441NRHypertensive heart disease (56.7%); Rheumatic heart disease (3.7%); Dilated cardiomyopathy (3.0%); Pericardial disease (1.8%); cor pulmonale (1.6%); Ischaemic heart disease (0.6%); Congenital heart disease (0.4%); diabetic heart disease (0.4%); thyroid heart disease (0.1%); Sickle cell cardiopathy (0.1%).NRHighOnwuchekwa, 2009 [@bib8]NigeriaWesternNRCross-sectionalHospital-basedRetrospectiveCongestive cardiac failure cases admitted and/or discharged from the medical wardsNo57.254.418--100423Framingham criteriaHypertensive heart disease (56.3%); Cardiomyopathies (12.2%); Chronic renal failure (7.80%); Severe anemia (4.72%); Rheumatic heart diseases (4.26%). Cor pulmonale (2.13%); Congenital valvular heart disease (0.24%); Ischemic heart disease (0.24%); Missing (11.11%)12-lead ECG; echocardiographyModerateDamasceno, 2012 [@bib10]The THESUS-HF registrySSA--CohortHospital-basedProspectivePatients admitted with acute heart failureNo49.252.3˃121006European Society of Cardiology (ESC) guidelines on HFHypertensive heart disease (45.4); Idiopathic dilated cardiomyopathy (18.8%); Rheumatic heart disease (14.3%); Ischaemic heart disease (7.7%); Peripartum cardiomyopathy (7.7%); Pericardial tamponade (6.8%); HIV cardiomyopathy (2.6%); Endomyocardial fibrosis (1.3%).12-lead ECG; echocardiography; stress testModerateKwan, 2013 [@bib12]RwandaEasternRuralCross-sectionalHospital-basedRetrospectiveHeart failure patients treated between November 2006 and march 2011No30.0NRNR138NRDilated cardiomyopathy (54%), Rheumatic heart disease (25%), hypertensive heart disease (8%) and ischaemic heart disease (0%)NRModerateMassouré, 2013 [@bib13]DjiboutiEasternNRCohortHospital-basedProspectiveAdults hospitalized for heart failureNo84.055.827--7545Framingham criteriaCoronary artery disease (62%); hypertensive heart disease (18%); rheumatic valvular disease (13%) and primary dilated cardiomyopathy (7%)12-lead ECG; echocardiography; stress testModerateOjji, 2013 [@bib14]NigeriaWesternUrbanCross-sectionalHospital-basedProspectivePatients with novo presentations of heart diseaseNo49.349.0NR1515European Society of Cardiology (ESC) guidelines on HFHypertensive heart disease (60.6%); Idiopathic dilated cardiomyopathy (12.0%); Valvular rheumatic heart disease (8.6%); peripartum cardiomyopathy (5.3%); Alcoholic cardiomyopathy (4.2%); Thyrotoxic heart disease (2.9%); right heart failure (2.5%); Ischaemic heart disease (0.4%)ECG; Cardiac enzymes; EchocardiographyHighMakubi, 2014 [@bib16]TanzaniaEasternUrbanCohortHospital-basedProspectivePatients ≥18 years of age with heart failure defined by the Framingham criteriaNo49.055.0≥18427Framingham criteriaHypertensive heart disease (45%); Cardiomyopathy (28%); Rheumatic heart disease (12%); Ischaemic heart disease (9%); Others^a^ (6%)12-lead ECG; echocardiography; angiographyHighOgah, 2014 [@bib17]NigeriaWesternUrbanCross-sectionalHospital-basedProspectivePatients presenting with acute heart failureNo54.956.4NR452Framingham criteria and ESCHypertensive heart disease (78.5%); Dilated cardiomyopathy (7.5%); Cor pulmonale (4.4%); Pericardial disease (3.3%); Rheumatic heart disease (2.4%); Ischaemic heart disease (0.4%)12-lead ECG and EchocardiographyHighPio, 2014 [@bib18]TogoWesternUrbanCross-sectionalHospital-basedProspectiveHospitalized patients with heart failureNo48.252.218--106297European Society of Cardiology (ESC) guidelines on HFHypertensive heart disease (43.1%); Ischaemic heart disease (19.2%); Peripartum cardiomyopathy (11.8%); valvulopathies (11.8%); HIV-related cardiopathy (3.4%); Thyrotoxic heart disease (3%); Cor pulmonale (2.7%); congenital cardiopathies (2.7%); Chronic alcoholism (2%) and idiopathic (5.9%).ECG; Cardiac enzymes; EchocardiographyHighPio, 2014 [@bib19]TogoWesternUrbanCross-sectionalHospital-basedRetrospectiveFiles of patients hospitalized with heart failureNoNR36.518--45376NRHypertensive heart disease (42.8%); Valvulopathies (18.1%); Peripartum cardiomyopathy (15.4%); Idiopathic dilated cardiomyopathy (5.8%); Alcoholic cardiomyopathy (3.2%); IHD (2.7%); Congenital cardiopathy (2.7%); Cor pulmonale (2.1%); thyrotoxic heart failure (1.8%); Pericardial tamponade (1.1%) and HIV-associated myocarditis (1.1%)ECG; Cardiac enzymes; EchocardiographyLowDokainish, 2015 [@bib22]The INTER-CHF registrySSA--CohortHospital-basedProspective, international, multicenterAmbulatory and hospitalized adult patients with heart failureYes51.853.4≥181294Boston criteria of HFHypertensive heart disease (35%); Ischaemic cardiomyopathy (20%); Idiopathic dilated cardiomyopathy (14.5%); Valvular rheumatic heart disease (7.2%); Endocrine/metabolic heart disease (5.3%); Vavlular non-rheumatic heart disease (2.3%); Alcohol/drug induced cardiopathy (0.7%); HIV cardiomyopathy (0.7%).12-lead ECG; echocardiographyModerateAnsa, 2016 [@bib24]NigeriaWesternNRCross-sectionalHospital-basedRetrospective medical record reviewAll cardiovascular admissions to the medical wardsNoNRNR≥18144NRHypertensive heart disease (48.6%); dilated cardiomyopathy (35.4%); Anaemia (14.6%) and Rheumatic heart disease (1.4%)NRLowAbebe 2016 [@bib25]EthiopiaEasternUrbanChart reviewHospital-basedRetrospectiveMedical records of patients admitted for heart failureNR30.253.6NR311NRValvular heart disease (40.8%); Hypertensive heart disease (16.1%); Ischaemic heart disease (15.8%); Dilated cardiomyopathy (12.5%), Cor pulmonale (4.5%); Others (10.3%)NRModerateKingery, 2017 [@bib27]TanzaniaEasternUrbanCohortHospital-basedProspectiveMedical inpatients admitted for heart failureNo44.152.0≥18145Framingham criteria of HFHypertensive heart disease (42.8%); dilated cardiomyopathy (19.3%); Valvular heart disease (16.6%); cor pulmonale (7.6%); ischaemic heart disease (6.2%); Other causes (7.6%)12-lead ECG; echocardiographyHighBoombhi, 2017 [@bib28]CameroonCentralUrbanCross-sectionalHospital-basedRetrospectivePatients hospitalized for acute heart failure, diagnosed on clinical and/or ultrasound evidenceNo42.761,516--95148NRHypertensive heart disease (30.16%); Dilated cardiomyopathy (28.57%); Valvular heart disease (11.90%); Chronic cor pulmonale (8.73%); Ischemic heart disease (6.35%); Pericardial diseases (3.96%); Peripartum cardiomyopathy (3.18%)12-lead ECG; echocardiographyLowTraore, 2017 [@bib29]Ivory CoastWesternUrbanCross-sectionalHospital-basedRetrospectivePatients hospitalized for heart failureNo51.0NRNR257NRHypertensive heart disease (22.9%); Dilated cardiomyopathy (55.57%); Valvular heart disease (6.76%); Ischemic heart disease (11.23%); Other (9.9%)Echocardiography ± coronarographyLow[^3]Table 6Summary of studies reporting on pharmacologic treatment of heart failure in sub-Saharan Africa.Table 6First name of author, publication yearCountryRegionAreaStudy designStudy settingData collectionRandom samplingMale (%)Mean age (in years)Age range (in years)Sample sizeCriteria for diagnosis of HFTreatment of heart failureStudy qualityKingue, 2005 [@bib10]CameroonCentralUrbanCross-sectionalHospital-basedRetrospective and prospectiveNo59.357.3≥16167NRLoop diuretics (90%); angiotensin-converting enzyme inhibitor (ACEI) (64.7%); beta-blockers (19.8%); digoxin (30.5%); aldosterone antagonists (25.5%)ModerateStewart, 2008 [@bib7]South AfricaSouthernUrbanCross-sectionalHospital-basedProspectiveNo43.055.0NR844ESCLoop or thiazide diuretic (68%); ACEI (57.7%); beta-blocker (45.6%); digoxin (19%); aldosterone antagonist (42%); calcium channel blocker (18%)HighOgah, 2014 [@bib26]NigeriaWesternUrbanCohortHospital-basedProspectiveNo54.956.4NR452Framingham criteria and ESCLoop diuretic (88.1%); ACEI (99.1%); beta-blockers (9.1%) digoxin (72.3%); long-acting calcium-channel blockers (26.8%); combined hydralazine and isosorbide dinitrate (14.4%)HighDamasceno, 2012 [@bib17]THESUS-HF RegistrySSANRCohortHospital-basedProspectiveNo49.252.3˃121006ESCLoop diuretic (79%); ACEI/angiotensin receptor blocker (ARB) (82%); beta-blockers (30%); Digoxin (60%); Aldosterone antagonist (75%);ModerateMakubi, 2014 [@bib18]TanzaniaEasternUrbanCohortHospital-basedProspectiveNo49.055.0≥18427Framingham criteriaLoop diuretics (88%); ACEI/ARB (92%); β-Blockers (42%); Digoxin (39%); Aldosterone antagonist (72%); Calcium channel blockers (19%); Nitrates (64%); Hydralazine (4%)HighDokainish, 2016 [@bib19]INTER-CHF registrySSABothCohortHospital-basedProspective, international, multicenterNo51.853.4≥181294Boston criteria of HFDiuretic (93.7%); ACEI/ARB (77.1%); β-Blockers (48.3%); Digoxin (31.9%); Aldosterone Inhibitors (59.4%);ModerateBoombhi, 2017 [@bib29]CameroonCentralUrbanCross-sectionalHospital-basedRetrospectiveNo42.761.516--96148NRDiuretics (93.2%); ACEI/ARB (50%); Beta-blockers (20.6%)LowBonsu, 2017 [@bib30]GhanaWesternUrbanCohortHospital-basedRetrospectiveNo45.660.3≥181488Framingham criteria of HFDiuretics (68.4%); ACEI/ARB (62%); β-Blockers (32.5%); Digoxin (16.3%); Aldosterone antagonist (28%); Calcium channel blockers (44.9%); Nitrates (2.1%)LowMwita, 2017 [@bib31]BotswanaSouthernUrbanCohortHospital-basedProspectiveNo53.954.220--89193NRACEI/ARB (67.4%); β-Blockers (72.1%); Loop diuretics (86%); Digoxin (22.1%); Aldosterone antagonist (59.9%)ModerateTable 7Summary of studies reporting on the mortality rate and/or predictors of mortality among heart failure patients in sub-Saharan Africa.Table 7First name of author, publication yearCountryRegionAreaStudy settingData collectionRandom samplingStudy PopulationMale (%)Mean age (in years)Age range (in years)Sample sizeDuration of follow-upMortality ratePredictor(s) of mortality (HR^\*^ or OR^\*\*^)Study qualityFamiloni, 2007 [@bib4]NigeriaWesternSemi-UrbanHospital-basedProspectiveNoAdult patients ([\>]{.ul}18 years) admitted for acute heart failure67.157.6NR823 years3-year mortality rate=67.1%Age (HR=0.997); Systolic blood pressure (HR=1.002); Congestion score (HR=1.007)ModerateMaro, 2009 [@bib9]TanzaniaEasternUrbanHospital-basedProspectiveNoPatients admitted for congestive heart failure55.0NRNR36012 months360-day mortality rate=21.9%NRModerate                                Chansa, 2012 [@bib11]ZambiaSouthernUrbanHospital-basedProspectiveNoAdult patients ([\>]{.ul}18 years) admitted for acute heart failure4150NR39030 daysIn-hospital mortality rate=24.1%Left ventricular ejection fraction \<40% (HR=1.93); NYHA class IV (HR=1.92); Serum urea nitrogen \>15 mmol/L (HR=2.10); Haemoglobin levels \<12 g/dL (HR=1.34); Systolic blood pressure \<115 mmHg (HR=1.92)Moderate30-day mortality rate=35%                                Sliwa, 2013 [@bib15]The THESUS-HF registrySSA--Hospital-basedProspectiveNoPatients presenting with acute heart failure49.152.3NR1006Six months60-day mortality rate=9.5%Malignancy (HR=5.04); History of cor pulmonale (HR=2.50); Serum urea nitrogen (HR=1.39); Systolic blood pressure (HR=0.91); Rales (HR=2.18); West region (HR=1.83)High180-day mortality rate=15.0%Massouré, 2013 [@bib13]DjiboutiEasternUrbanHospital-basedProspectiveNoAdult patients ([\>]{.ul} 18 years) admitted for heart failure8455.827--754514.4 monthsMortality rate=18.0%NRModerateOkello, 2014 [@bib21]UgandaEasternNRHospital-basedRetrospectiveNoPatients admitted for acute heart failure30.352NR27413 monthsIn-hospital mortality rate=18.3%Hypotension on admission (adjusted OR=4.6); Reduced left ventricular ejection fraction (adjusted OR=7.6)LowMakubi, 2014 [@bib16]TanzaniaEasternUrbanHospital-basedProspectiveNoAdult patients ([\>]{.ul}18 years) with heart failure49.055[\>]{.ul}184277 months22.4 per 100 person-yearsCreatinine clearance (HR=0.98); Pulmonary hypertension (HR=2.11); Anaemia (HR=2.27); No formal education (HR=2.34); Inpatient (HR=3.23); Atrial fibrillation (HR=3.37).HighAli, 2016 [@bib26]EthiopiaEasternUrbanHospital-basedProspectiveNoAdult patients ([\>]{.ul} 18 years) admitted for heart failure50.750.9[\>]{.ul}181529 monthsIn-hospital mortality rate=3.9%NRLowAbebe, 2016 [@bib25]EthiopiaEasternUrbanHospital-basedRetrospectiveNRAdult patients admitted for HF30.253.8[\>]{.ul}1831125 monthsMortality rate=14.1%Advanced age (HR=1.05), Hyponatremia (HR=0.91), elevated creatinine levels (HR=1.97), and absence of medication (spironolactone \[HR=0.34\], ACEI \[HR=0.26\] and statin \[HR=0.19\])Moderate                                Kingery, 2017 [@bib27]TanzaniaEasternUrbanHospital-basedProspectiveNoAdult patients ([\>]{.ul}18 years) admitted for heart failure38.350.8[\>]{.ul}1814512 monthsIn-hospital mortality rate=25.2%Low eGFR (HR=2.94); Proteinuria (HR=2.03).High360-day mortality rate=57.9%Bonsu, 2017 [@bib30]GhanaWesternUrbanHospital-basedRetrospectiveNoAdult patients ([\>]{.ul} 18 years) admitted for heart failure45.660.3[\>]{.ul}1814885 years5-year mortality rate=31.7%Age (HR=1.01); NYHA IV (HR=1.96); Ejection fraction (HR=0.99); LDLC-C (HR=1.1); Chronic kidney disease (HR=1.74); Atrial fibrillation (HR=1.26); Anaemia (HR=1.40); Diabetes mellitus (HR=1.50); Statin (HR=0.70); Aldosterone antagonists (HR=0.81)High                                Mwita, 2017 [@bib31]BotswanaSouthernUrbanHospital-basedProspectiveNoAdult patients ([\>]{.ul}18 years) admitted for acute heart failure53.954.220--891931 yearIn-hospital mortality rate=10.9%Advanced age; Lower haemoglobin level; Lower eGFR; Lower serioum sodium levels; Higher length of hospital stay; Higher serum creatinine levels; Higher serum urea levels; Higher serum NT-proBNP levelsModerate30-day mortality rate=14.7%180-day mortality rate=30.8%Pallangyo 2017 [@bib32]TanzaniaEasternUrbanHospital-basedProspectiveNoAdult patients ([\>]{.ul}18 years) admitted for heart failure43.546.4[\>]{.ul}18463180 days180-day mortality rate=57.8%Renal dysfunction (HR=1.9); Severe anaemia (HR=1.8); Hyponatraemia (HR=2.2); Rehospitalisation (HR=4.3); Cardiorenal anaemia syndrome (HR=2.1)High                                Sani, 2017 [@bib33]The THESUS-HF registrySSA--Hospital-basedProspectiveNoPatients presenting with acute heart failure49.252.3[\>]{.ul}12954180 daysNRPredictors of mortality within 60 days: Heart rate (HR=1.07); left atrial size (HR=1.00)LowPredictors of mortality within 180 days: Heart rate \>80bpm (HR=1.25); left ventricular posterior wall thickness in diastole \>9 mm (HR=1.32); Presence of aortic stenosis (HR=3.60)[^4]

Data were analyzed using the '*meta'* package of R software. A random-effects meta-analysis model was used to pool prevalence estimates after stabilization of the variance of the study-specific prevalence using the Freeman-Tukey single arc-sine transformation [@bib37]. The Egger\'s test was used to assess publication bias which was considered significant if the p-value \<0.1. Summary statistics from meta-analyses of prevalence studies on the medications used to treat heart failure in sub-Saharan Africa are presented in [Table 8](#t0040){ref-type="table"}.Table 8Summary statistics from meta-analyses of prevalence studies on the medications used to treat heart failure in sub-Saharan Africa.Table 8**TreatmentN studiesN participants% (95% confidence interval)I² (95% confidence interval)H (95% confidence interval)P heterogeneityP Egger testACEI/ARB**9569275.5 (64.4--85.1)98.8 (98.4--99.0)8.9 (7.8--10.2)\<0.00010.879**Aldosterone antagonists**6492551.5 (32.4--70.3)99.4 (99.3--99.6)13.4 (11.8--15.2)\<0.00010.807**Digoxin**7502731.5 (19.4--45.0)98.9 (98.6--99.2)9.6 (8.3--11.2)\<0.00010.924**Loop diuretics**9569281.6 (72.7--89.1)98.4 (97.8--98.8)7.8 (6.7--9.0)\<0.00010.806**β-Blockers**9569231.4 (22.6--41.0)98.1 (97.4--98.6)7.3 (6.3--8.5)\<0.00010.549[^5]

These data are attached to a systematic review and meta-analysis published in the International Journal of Cardiology [@bib38].
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[^1]: HF=Heart failure; THESUS-HF=sub-Saharan Africa Survey for Heart Failure; INTER-CHF=INTERnational Congestive Heart Failure; NR=Not reported; NA=Not applicable; SSA=Sub-Saharan Africa.

[^2]: NR=Not reported.

[^3]: Others^a^=Tuberculosis; HIV-related cardiomyopathy; endomyocardial fibrosis; obstructive pulmonary disease; IHD=Ischaemic heart disease; ECG=Electrocardiography; HF=Heart failure; THESUS-HF=sub-Saharan Africa Survey for Heart Failure; INTER-CHF=INTERnational Congestive Heart Failure; ESC=European Society of Cardiology; NR=not reported.

[^4]: HR\*=Hazard ratio; OR\*\*=Odd\'s ratio; NYHA=New York Heart Association; bpm=Beats per minute; NR=Not reported; eGFR=Estimated glomerular filtration rate.

[^5]: ACEI=Angiotensin II enzyme inhibitor; ARB=Angiotensin receptor blocker; N=frequency; CI=confidence interval.
